NON-FINAL REJECTION
Receipt is acknowledged of Applicants' Amendments and Remarks, filed Feb. 25, 2026 and Jun. 25, 2026.
Rejections and/or objections not reiterated from previous Office Actions are hereby withdrawn. The rejections and/or objections set forth below are either maintained or newly applied, and constitute the complete set presently applied to the instant claims.
STATUS OF THE CLAIMS
Claims 14, 15, and 18-33 have been canceled.
Claim 1 has been amended and incorporates no new matter.
No new claims have been added.
Claims 9-13, 16, 17, and 34-44 stand withdrawn as drawn to nonelected inventions and/or species.
Thus, claims 1-8 now represent all claims currently pending and under consideration.
INFORMATION DISCLOSURE STATEMENT
The information disclosure statements (IDS) submitted on Feb. 25, 2026 and May 12, 2026 were filed after the mailing date of the non-final action on Oct. 2, 2025. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statements are being considered by the examiner.
RESPONSE TO ARGUMENTS
Applicant’s amendments overcome the rejections under 35 U.S.C. § 103 over Liu et al. (WO2017/136708) in view of Meanwell (2018); and on the ground of obviousness-type double patenting over claim 2 of U.S. Patent No. 11,708,391 in view of Meanwell (2018). Therefore, these rejections are withdrawn.
NEW REJECTIONS
Claim Rejections - 35 U.S.C. § 112(d) – Improper Dependency
The following is a quotation of 35 U.S.C. 112(d):
(d) REFERENCE IN DEPENDENT FORMS.—Subject to subsection (e), a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
The following is a quotation of pre-AIA 35 U.S.C. 112, fourth paragraph:
Subject to the following paragraph [i.e., the fifth paragraph of pre-AIA 35 U.S.C. 112], a claim in dependent form shall contain a reference to a claim previously set forth and then specify a further limitation of the subject matter claimed. A claim in dependent form shall be construed to incorporate by reference all the limitations of the claim to which it refers.
1. Claim 2 is rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Specifically, claim 2 reads as follows:
PNG
media_image1.png
124
696
media_image1.png
Greyscale
However, this limitation fails to further limit claim 1, because the indicated carbon atom is chiral, which will, of necessity, be in either the R or S configuration.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
2. Claims 6 and 7 are rejected under 35 U.S.C. 112(d) or pre-AIA 35 U.S.C. 112, 4th paragraph, as being of improper dependent form for failing to further limit the subject matter of the claim upon which it depends, or for failing to include all the limitations of the claim upon which it depends.
Specifically, claim 6 is drawn to the compound of claim 3, wherein the compound “is an inhibitor of macrophage migration inhibitory factor (MIF) nuclease activity and an inhibitor of parthanatos mediated cell death.” Similarly, claim 7 is drawn to the compound of claim 3, wherein the compound “is an inhibitor of parthanatos mediated cell death.”
However, these recitations fail to further limit claim 3. As evidenced by the specification (Table 4), the recited properties are intrinsic to compound 121 as recited by claim 3.
Applicant may cancel the claim(s), amend the claim(s) to place the claim(s) in proper dependent form, rewrite the claim(s) in independent form, or present a sufficient showing that the dependent claim(s) complies with the statutory requirements.
Allowable Subject Matter
Claims 1, 3-5, and 8 are allowed.
Reasons for Allowance
Liu et al. (WO 2017/136708, of record) disclose compounds of generic formula (E) (paras. [0007], [0017]), and teach and suggest a compound having the structural formula:
Compound of Liu et al.
Claimed Formula (VII)
PNG
media_image2.png
316
430
media_image2.png
Greyscale
PNG
media_image3.png
272
448
media_image3.png
Greyscale
which falls within the scope of claimed formula (VII), except for the fluorine at R2.
Liu et al. do not disclose, teach, or suggest that the phenyl ring (circled) can be substituted by fluorine, as required by claim 1. The compounds of Liu et al. contain approximately 81 possible fluorination sites; and Liu et al. suggest that many of these sites may be halogenated. However, none of the compounds exemplified by Liu et al. contain a fluorine; nor do Liu et al. suggest a halogen substituent specifically at position R2 of formula (VII), or anywhere on the same phenyl ring.
Thus, Liu et al. do not provide any guidance as to which particular site would be beneficial to fluorinate; nor does Meanwell (J. Med. Chem. 61, 5822-5880 (2018), of record) disclose, teach, or suggest any particular sites to favor over others for fluorination.
CONCLUSION
Any inquiry concerning this communication or earlier communications from the examiner should be directed to SARA E. TOWNSLEY whose telephone number is 571-270-7672. The examiner can normally be reached on Mon-Fri from 10:00 am to 6:00 pm (EST). If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jeff S. Lundgren, can be reached at 571-272-5541. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.
Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
/SARA E. TOWNSLEY/Examiner, Art Unit 1629